Wall M E, Wani M C, Nicholas A W, Manikumar G, Tele C, Moore L, Truesdale A, Leitner P, Besterman J M
Research Triangle Institute, Research Triangle Park, North Carolina 27709.
J Med Chem. 1993 Sep 3;36(18):2689-700. doi: 10.1021/jm00070a013.
A large number of camptothecin (CPT) analogs have been prepared in the 20S, 20RS, and 20R configurations with a number of ring A substituents. Topoisomerase I (T-I) inhibition data (IC50) have been obtained by standard procedures. In general, substitution at the 9 or 10 positions with amino, halogeno, or hydroxyl groups in compounds with 20S configuration results in compounds with enhanced T-I inhibition. Compounds in the 20RS configuration were less active in vitro and in vivo and those in the 20R configuration were inactive. Compounds with 10,11-methylenedioxy substitution on ring A displayed a marked increase in potency in the T-I inhibition assay. The activities of some of the analogs as determined in a variety of in vivo assays including the L-1210 mouse leukemia assay were, in general, in accord with T-I inhibition. A number of water-soluble analogs such as 20-glycinate esters, 9-glycinamides, or hydrolyzed lactone salts were prepared and tested in in vitro and in vivo assays. In general, these compounds were less active than CPT both in terms of T-I inhibition and life prolongation in the L-1210 assay. However, certain 20-glycinate esters showed good in vivo activity after iv administration.
人们已经制备了大量具有20S、20RS和20R构型且带有多个A环取代基的喜树碱(CPT)类似物。通过标准程序获得了拓扑异构酶I(T-I)抑制数据(IC50)。一般来说,在具有20S构型的化合物中,在9位或10位用氨基、卤代基或羟基进行取代会得到T-I抑制作用增强的化合物。20RS构型的化合物在体外和体内活性较低,而20R构型的化合物则无活性。在A环上具有10,11-亚甲基二氧基取代的化合物在T-I抑制试验中显示出效力显著增加。在包括L-1210小鼠白血病试验在内的多种体内试验中测定的一些类似物的活性,总体上与T-I抑制作用一致。制备了一些水溶性类似物,如20-甘氨酸酯、9-甘氨酰胺或水解内酯盐,并在体外和体内试验中进行了测试。一般来说,这些化合物在T-I抑制和L-1210试验中的生命延长方面均比CPT活性低。然而,某些20-甘氨酸酯经静脉给药后显示出良好的体内活性。